3.2 Quality Assessment The risk of bias for the included trials is presented in Supplementary Figure S1
The results were heterogeneous: some trials, such as AMPLITUDE-O and SELECT, demonstrated significant reductions in HF-related endpoints, whereas others, like LEADER, showed only non-significant favourable trends
[142] By contrast, in the United States, due to high costs, some health plans do not cover weight-loss drugs like semaglutide and tirzepatide
Skovlund SE, Nicolucci A, Balk-Mller N et al (2021) Perceived benefits, barriers, and facilitators of a digital patient-reported outcomes tool for routine diabetes care: protocol for a national, multicenter, mixed methods implementation study
Candidacy is determined with a licensed provider after reviewing your medical history, current medications, and goals
A key improvement is in glycemic control